Lucid Diagnostics Inc. (LUCD) Institutional Ownership

Ownership Summary

Lucid Diagnostics Inc. (NASDAQ:LUCD) showed up in the 13F filings of 87 institutional investors as of December 2025.

• They owned 29.7% of outstanding stock in December 2025, down from 32.6% the prior quarter.
• Their total shares held in LUCD increased 15.74% quarter over quarter, and separately, investors owning Lucid Diagnostics increased 163.64% from a year ago.
• During the quarter, 47 of these 87 funds increased positions in LUCD, 17 reduced exposure, and 23 held steady.
• Institutional investors collectively held 32.15Mn shares in Lucid Diagnostics as of December 2025, up by 4.37Mn shares quarter on quarter, and up 28.78Mn shares year over year.
• As of December 31, 2025, the biggest holder of Lucid Diagnostics is VANGUARD GROUP INC at 4.97Mn shares, representing 4.59% of shares outstanding.
• The most significant purchases of LUCD for the quarter ending December 2025 came from Aberdeen Group plc (957.89K), BlackRock, Inc. (643.35K), RENAISSANCE TECHNOLOGIES LLC (532.89K), VANGUARD GROUP INC (444.61K), GEODE CAPITAL MANAGEMENT, LLC (352.65K).
• The largest sellers of Lucid Diagnostics for the quarter ending December 2025 were LUMINUS MANAGEMENT LLC (541.84K), Goldman Sachs Group Inc (270.88K), Jpmorgan Chase & Co (30.69K), RHUMBLINE ADVISERS (13.62K), Bank Of America Corp /De/ (11.01K).
• Lucid Diagnostics's 10 largest shareholders as of December 2025 include VANGUARD GROUP INC (4.97Mn), BlackRock, Inc. (4.31Mn), MASTERS CAPITAL MANAGEMENT LLC (4.0Mn), Aberdeen Group plc (3.46Mn), Two Seas Capital LP (3.0Mn), GEODE CAPITAL MANAGEMENT, LLC (2.03Mn), State Street Corp (1.35Mn), PERKINS CAPITAL MANAGEMENT INC (1.13Mn), Wells Fargo & Company/Mn (919.48K), RENAISSANCE TECHNOLOGIES LLC (826.53K) per Business Quant data.